| SEALSQ Announces Agenda of its 2026 Annual General Meeting of Shareholders |
Globe Newswire |
04/17 |
16:05 |
| Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 |
Globe Newswire |
04/17 |
16:05 |
| QuasarEdge Acquisition Corporation Announces Exercise of Over-Allotment Option |
Globe Newswire |
04/17 |
16:05 |
| VALUE LINE, INC. DIVIDEND HAS JUST BEEN RAISED FROM $1.30 TO $1.40 (ANNUALIZED) – ITS 12TH CONSECUTIVE INCREASE |
Globe Newswire |
04/17 |
16:03 |
| Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
Globe Newswire |
04/17 |
16:02 |
| Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types |
Globe Newswire |
04/17 |
16:01 |
| Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting |
Globe Newswire |
04/17 |
16:01 |
| Hingham Savings Reports First Quarter 2026 Results |
Globe Newswire |
04/17 |
16:01 |
| New Era Energy & Digital Announces Appointment of Andy Casazza as Chief Corporate Officer |
Globe Newswire |
04/17 |
16:01 |
| Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 |
Globe Newswire |
04/17 |
16:01 |
| Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities |
Globe Newswire |
04/17 |
16:00 |
| Genesis Revival Claims Evaluated: Analyzing the Pineal Gland Support Ingredients, Side Effects Risk and User Complaints |
Globe Newswire |
04/17 |
15:48 |
| MLG Capital Recognized by National Multifamily Housing Council as a 2026 Top 50 Owner |
Globe Newswire |
04/17 |
15:40 |
| NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET |
Globe Newswire |
04/17 |
15:37 |
| Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 |
Globe Newswire |
04/17 |
15:15 |
| Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial |
Globe Newswire |
04/17 |
15:10 |
| Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details |
Globe Newswire |
04/17 |
15:08 |
| Brazilian Wood Claims Evaluated: Discover the Male Enhancement Hardening Pill Truth by SuperNatural Man |
Globe Newswire |
04/17 |
15:07 |
| Kairos Power Breaks Ground on Hermes 2 Demonstration Plant |
Globe Newswire |
04/17 |
15:06 |
| PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma |
Globe Newswire |
04/17 |
15:00 |
| Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 |
Globe Newswire |
04/17 |
15:00 |
| Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026 |
Globe Newswire |
04/17 |
15:00 |
| Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform |
Globe Newswire |
04/17 |
15:00 |
| MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer |
Globe Newswire |
04/17 |
15:00 |
| Ohio No. 1 State in the Midwest for Business, According to CEOs Nationwide |
Globe Newswire |
04/17 |
14:47 |
